Skip to content
StackItSmart
BHuman cohort / observational

Resveratrol

Resveratrol (trans-3,4',5-trihydroxystilbene) is a plant polyphenol (from grapes, red wine, Polygonum cuspidatum) sold as an "organ-support"/anti-aging ancillary supplement. It is one of the more heavily human-studied nutraceuticals on PubMed, yet oral bioavailability is very low because of near-complete first-pass sulfation and glucuronidation, so most marketed longevity/organ-protection claims rest on preclinical or surrogate-marker data, not clinical outcomes. Human RCTs and meta-analyses show only modest, inconsistent effects on blood pressure and glycemic markers. The most important real dangers are: dose-dependent gastrointestinal intolerance (diarrhea, nausea, abdominal pain) at grams-per-day doses; a documented renal-toxicity/renal-failure signal when high-dose micronized resveratrol (SRT501) was given to relapsed/refractory multiple myeloma patients; plausible bleeding and drug-interaction risk via antiplatelet activity and cytochrome-P450/UGT inhibition; and phytoestrogenic activity of uncertain clinical significance in hormone-sensitive conditions. It is not an anabolic, a SERM, or a hormone; it does not "boost" performance. Anyone using it should treat it as an unproven adjunct, not a therapy, and coordinate with a clinician—especially if on anticoagulants, with kidney disease, or with a hormone-sensitive cancer.

Clinical readoutAncillary · organ-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
Parent trans-resv…
Route
Oral
Evidence
B
Active
Systemic parent exposur…
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Parent trans-resveratrol terminal half-life is short: roughly 1-3 h after single oral doses and 2-5 h after repeated dosing, with high interindividual variability (coefficient of variation >40%) and circadian variation in absorption (PMID 19194969).
Pharmacology

Mechanism of action

Resveratrol is a pleiotropic polyphenol without a single defined receptor target. Preclinically it activates AMP-activated protein kinase (AMPK) and increases SIRT1 (sirtuin-1) and PGC-1alpha protein, producing "calorie-restriction-mimetic" shifts in mitochondrial and energy metabolism; in a human RCT in obese men, 150 mg/day for 30 days activated muscle AMPK, raised SIRT1 and PGC-1alpha, and improved mitochondrial respiration (PMID 22055504). It also has antioxidant/free-radical-scavenging, anti-inflammatory (NF-kB downregulation), and antiplatelet properties, and lowers circulating IGF-1 and IGFBP-3 after repeated high dosing (PMID 20935227). It is a phytoestrogen with mixed estrogen-receptor agonist/antagonist activity in vitro (PMID 11081378). Much of the mechanistic literature is preclinical, and the very low systemic exposure of parent drug in humans makes it uncertain which mechanisms are actually engaged at achievable plasma levels (PMID 26221416).
Kinetics

Pharmacokinetics

Half-life

Parent trans-resveratrol terminal half-life is short: roughly 1-3 h after single oral doses and 2-5 h after repeated dosing, with high interindividual variability (coefficient of variation >40%) and circadian variation in absorption (PMID 19194969).

Active duration

Systemic parent exposure is brief (hours), which is why clinical trials dose two-to-six times daily; sulfate/glucuronide conjugates persist longer and reach much higher plasma concentrations than parent (PMID 20935227).

Route

Oral (capsules/tablets). Presented here only for monitoring, dosing-interval understanding, and washout timing—not for evading detection.

Metabolism & clearance

Extensive presystemic (gut wall and hepatic) phase-II metabolism: absorption is high but first-pass sulfation and glucuronidation leave little free parent drug. Major circulating metabolites are resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide, and resveratrol-4'-O-glucuronide, whose Cmax and AUC can exceed parent by up to ~20-fold; conjugates are cleared via renal and biliary routes (PMID 20935227, PMID 26221416).

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Modest, dose-dependent lowering of systolic blood pressure at higher doses (>=150-300 mg/day) in meta-analysis; no consistent effect on diastolic BP (PMID 24731650, PMID 29359958).
  • Small improvements in fasting glucose, fasting insulin, and HOMA-IR in type 2 diabetics by meta-analysis, without meaningful HbA1c change (PMID 29018489).
  • Calorie-restriction-like metabolic changes in obese men: reduced sleeping/resting metabolic rate, lower systolic BP, improved HOMA index, reduced circulating triglycerides, ALT, and inflammatory markers, and reduced hepatic lipid (PMID 22055504).
  • Reduction of ALT, inflammatory cytokines, and hepatic steatosis grade when added to lifestyle modification in NAFLD (PMID 25311610).
  • Lowered circulating IGF-1 and IGFBP-3 after 29 days of high-dose (0.5-5 g/day) repeated dosing (PMID 20935227).
  • No demonstrated ergogenic, anabolic, hormonal, or body-composition-optimizing effect; not a performance or physique agent.
Safety

Adverse effects by system

Cardiovascular

No cardiotoxic signal in human trials; effects trend favorable/neutral (modest systolic BP reduction at higher doses, no consistent DBP change). Because BP can fall, additive hypotension with antihypertensives is plausible though not well quantified (PMID 24731650, PMID 29359958, PMID 22055504).

Hepatic

Generally hepatically neutral-to-favorable in humans: blood chemistries stayed within normal range at 300-1000 mg/day for 90 days (PMID 24866496), and ALT fell in NAFLD and obese cohorts (PMID 25311610, PMID 22055504). No consistent human hepatotoxicity signal, but liver-panel monitoring is prudent given extensive hepatic metabolism.

Endocrine / HPTA

Resveratrol is a phytoestrogen with mixed estrogen-receptor agonist/antagonist activity in vitro (PMID 11081378); the clinical endocrine relevance in humans is not established and there is no adequate human data showing HPTA/testosterone axis suppression. Caution is warranted in hormone-sensitive conditions on mechanistic grounds only.

Reproductive

No adequate human reproductive-safety data. In animals, high-purity trans-resveratrol produced no adverse embryo-fetal or reproductive effects up to 750 mg/kg/day, but human pregnancy/lactation safety is unestablished and its phytoestrogenic activity argues for avoidance in pregnancy absent data (PMID 19505523, PMID 11081378).

Neuropsychiatric

No specific psychiatric adverse effects established in human trials; no adequate data indicating neuropsychiatric harm or benefit at supplement doses.

Renal

A renal-toxicity signal exists: in a phase 2 trial of high-dose micronized resveratrol (SRT501) plus bortezomib in relapsed/refractory multiple myeloma, cases of renal failure, dehydration, and vomiting were reported and the program was affected by nephrotoxicity concerns (PMID 23205612, PMID 34052324). Relevance to healthy users at supplement doses is unclear, but this is the most serious documented organ toxicity.

Hematologic

No hematologic toxicity in human trials, but resveratrol has antiplatelet activity, creating a theoretical bleeding risk especially with anticoagulants/antiplatelets. In vitro it was clastogenic (chromosomal aberrations in human lymphocytes) though non-genotoxic in the in vivo rat micronucleus assay (PMID 19505523).

Dermatologic

No clinically important dermatologic adverse effects reported in human oral trials; high-purity trans-resveratrol was non-irritating and non-sensitizing to skin/eyes in animal studies (PMID 19505523).

Recovery

HPTA suppression & recovery

Suppression: No established HPTA suppression; resveratrol is an organ-support polyphenol, not an androgen, SERM, or hormone, and there is no adequate human data showing suppression of the hypothalamic-pituitary-gonadal axis. It does show phytoestrogenic (mixed ER agonist/antagonist) activity in vitro (PMID 11081378), so an unquantified mechanistic endocrine effect cannot be fully excluded.

Because no meaningful HPTA suppression is documented, no resveratrol-specific recovery protocol applies. Anyone concerned about hormonal effects, using it alongside hormonal agents, or with a hormone-sensitive condition should have testosterone/estradiol/LH/FSH and relevant markers evaluated and managed by an endocrinologist rather than self-directing any recovery or restart strategy. Do not use any SERM or hormonal 'recovery' agent without physician supervision.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic renal function (serum creatinine, eGFR, BUN) given the myeloma renal-toxicity signalLiver panel (ALT, AST, ALP, bilirubin) given extensive hepatic metabolismBlood pressure (home and clinic), particularly if on antihypertensivesFasting glucose / HbA1c and, if diabetic, closer glucose monitoring for additive effectsCBC and, if on anticoagulants/antiplatelets, coagulation status (e.g., INR if on warfarin)

Cadence: Baseline before starting; recheck renal and liver panels and blood pressure at roughly 6-12 weeks, then periodically (e.g., every 3-6 months) with continued use; sooner if symptoms develop, doses are high (grams/day), or interacting drugs are added.

Warning signs — seek care
  • Reduced urine output, leg/facial swelling, or rising creatinine (possible renal injury) — stop and seek care
  • Persistent diarrhea, nausea, vomiting, or abdominal pain, especially at gram-level doses — dehydration risk
  • Unusual bruising, bleeding gums, blood in stool/urine, or nosebleeds (bleeding risk with antiplatelet/anticoagulant use)
  • Symptomatic low blood pressure (dizziness, fainting), especially with antihypertensives
  • Jaundice, dark urine, or right-upper-quadrant pain (hepatic warning signs)
Do not use if

Contraindications

  • Hormone-sensitive cancers or conditions (breast, uterine, prostate) — phytoestrogenic activity of uncertain clinical effect; use only under oncology guidance (PMID 11081378).
  • Multiple myeloma / active plasma-cell disorders — renal-failure signal with high-dose micronized resveratrol plus bortezomib (PMID 23205612).
  • Concurrent anticoagulant or antiplatelet therapy — additive bleeding risk from resveratrol's antiplatelet activity (mechanistic caution).
  • Pre-existing renal impairment — given the documented renal-toxicity signal, avoid high doses without nephrology input (PMID 23205612).
  • Pregnancy and breastfeeding — no adequate human safety data plus phytoestrogenic activity (PMID 19505523, PMID 11081378).
  • Use of narrow-therapeutic-index drugs metabolized by CYP3A4/CYP2C9 or UGT — potential pharmacokinetic interaction from enzyme inhibition.
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Treat resveratrol as an unproven adjunct, not a therapy: human benefits are modest, inconsistent, and mostly on surrogate markers—do not substitute it for evidence-based treatment of hypertension, diabetes, or liver disease.
  • Higher doses are not automatically better: grams-per-day doses (2.5-5 g) reliably cause diarrhea, nausea, and abdominal pain; if GI symptoms occur, reduce or stop and rehydrate.
  • Stop and seek medical care for reduced urine output, swelling, unexplained rising creatinine, jaundice, or significant bleeding/bruising.
  • If you take anticoagulants or antiplatelets (warfarin, DOACs, aspirin, clopidogrel), or narrow-therapeutic-index drugs metabolized by CYP3A4/CYP2C9/UGT, review resveratrol with your prescriber before use because of interaction and bleeding risk.
  • Avoid in pregnancy, breastfeeding, active multiple myeloma, significant kidney disease, and hormone-sensitive cancers unless a treating physician specifically approves.
  • Get baseline and periodic bloodwork (renal function, liver panel, glucose) and monitor blood pressure; involve a clinician rather than self-managing, especially if combining with medications.
  • Consider stopping several days before surgery or invasive procedures because of antiplatelet activity (discuss timing with your surgical team).
Evidence

Citations (13)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Parent trans-resveratrol has a short half-life (~1-3 h single dose, 2-5 h repeated), high interindividual variability, circadian absorption variation, and low plasma concentrations despite high oral doses; well tolerated in a rising multiple-dose RCT.

    RCTPMID 19194969 ↗

  2. 02

    Repeated high-dose resveratrol (0.5-5 g/day, 29 days) in healthy volunteers caused mild-to-moderate GI symptoms (diarrhea, nausea, abdominal pain) at 2.5 and 5 g; major plasma species are sulfate/glucuronide conjugates far exceeding parent; circulating IGF-1 and IGFBP-3 decreased.

    RCTPMID 20935227 ↗

  3. 03

    Resveratrol 300 and 1000 mg/day for 90 days in overweight older adults kept blood chemistries within normal range, was well tolerated, and modestly lowered glucose.

    RCTPMID 24866496 ↗

  4. 04

    In obese men, 150 mg/day for 30 days activated muscle AMPK, raised SIRT1 and PGC-1alpha, improved mitochondrial respiration, lowered systolic BP, HOMA index, triglycerides, ALT, and inflammatory markers (calorie-restriction-mimetic effects).

    RCTPMID 22055504 ↗

  5. 05

    Meta-analysis: resveratrol significantly lowers systolic BP only at higher doses (>=150 mg/day, -11.9 mmHg) with no significant effect on diastolic BP.

    Meta-analysisPMID 24731650 ↗

  6. 06

    Meta-analysis: overall no significant BP effect, but significant reductions in subgroups at >=300 mg/day and in diabetics; resveratrol was fairly well tolerated with no serious adverse events in most trials.

    Meta-analysisPMID 29359958 ↗

  7. 07

    Meta-analysis in type 2 diabetes: resveratrol improved fasting plasma glucose, fasting insulin, and HOMA-IR, with negligible HbA1c change.

    Meta-analysisPMID 29018489 ↗

  8. 08

    Phase 2 trial of high-dose micronized resveratrol (SRT501) plus bortezomib in relapsed/refractory multiple myeloma reported renal failure, dehydration, and vomiting (renal-toxicity signal).

    RCTPMID 23205612 ↗

  9. 09

    Review documenting resveratrol-induced nephrotoxicity in multiple myeloma patients as a development-limiting toxicity.

    ReviewPMID 34052324 ↗

  10. 10

    Resveratrol added to lifestyle modification in NAFLD reduced ALT, inflammatory cytokines, NF-kB activity, cytokeratin-18, and hepatic steatosis grade.

    RCTPMID 25311610 ↗

  11. 11

    Resveratrol is a phytoestrogen with mixed estrogen-receptor agonist/antagonist (SERM-like) activity relevant to hormone-sensitive tissues.

    ReviewPMID 11081378 ↗

  12. 12

    Resveratrol undergoes extensive first-pass sulfation/glucuronidation with rapid elimination and low free-parent bioavailability; conjugated metabolites dominate systemic exposure.

    ReviewPMID 26221416 ↗

  13. 13

    High-purity trans-resveratrol was non-irritating/non-sensitizing and non-mutagenic but clastogenic in vitro (human lymphocyte chromosomal aberrations), non-genotoxic in vivo, and produced no adverse effects up to 700 mg/kg/day (90-day) or reproductive effects up to 750 mg/kg/day in animals.

    PreclinicalPMID 19505523 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice